Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an eye drops solution for ocular use. It lowers intra‑ocular pressure and is used in the management of glaucoma and ocular hypertension in adults.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analog indicated for conditions that require reduction of intra‑ocular pressure. - Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. - Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma. - Secondary open‑angle glaucoma (e.g., pseudoexfoliative): provides pressure‑lowering effect similar to primary forms.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation or foreign‑body sensation. - Blurred vision: transient after instillation. - Periorbital skin darkening.

Serious or Rare Side Effects: - Severe eye inflammation (uveitis, iritis). - Allergic reactions: swelling, itching, rash. - Paradoxical increase in intra‑ocular pressure. - Vision loss: sudden or progressive. - Corneal edema or keratitis. - Macular edema, especially in diabetic patients.

Before using Monoprost, consider the following safety measures. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Contact lens wear: avoid during treatment as lenses may absorb the drug. - Intra‑ocular pressure monitoring: schedule regular assessments to gauge efficacy. - Concomitant prostaglandin analogs: avoid simultaneous use to prevent additive effects. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish pressure‑lowering effect. - Systemic prostaglandin synthesis inhibitors (e.g., indomethacin): could antagonize action.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure reduction, monitor for hypotony. - Carbonic anhydrase inhibitor eye drops: increased risk of ocular irritation. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): may enhance ocular side effects. - Topical corticosteroids: potential for increased intra‑ocular pressure, require close observation.